Let the inventions grow!

About us

From lab to market

We are here to help inventions grow. We are your new team member, who can help you make the journey from groundbreaking invention to market-storming product.

We are i&i Prague, a biotech hub located right in the centre of Europe, and our objective is to identify the potential of, and nurture, new inventions in MedTech, Biotech, Diagnostics and Drug Discovery by Central European scientists and researchers. We do this by sourcing or, in some cases, providing financial investment for your invention, then we will help you with product development and, ultimately, market entry.

Our background

We operate as a private company under the wings of the Czech Academy of Sciences and its Institute of Organic Chemistry and Biochemistry (IOCB). From 1994 to 2002, the IOCB was led by Dr. Antonín Holý, whose team  (Truvada, Atripla, Complera, Eviplera), invented and developed hugely effective and successful anti-HIV drugs. We believe that this is a legacy to build upon and that, with yours and our combined expertise, we can make this world a better place and help millions of people.



Read more

About us

Investment process


Submit your project

Submit your invention to i&i Prague for evaluation. i&i Prague team will contact you within a week for further discussion of your project.

Start now


Project evaluation and investment

Selected projects will be subject to thorough evaluation including technical, marketing and business aspects. We will finalise a business plan in collaboration, and submit it to the i&i Prague Investment Board for approval.


Launching the project

Once approved, your project will be covered by an investment or collaborative agreement and will be run as either a spin-off company with defined co-ownership, or as a collaborative project with shared IP rights in defined ratio.


Project management

Each project will have an agreed action plan and a dedicated team led by a project manager. This team will be responsible for implementation and day-to-day management. Additionally, a nominated steering committee (or supervisory board) will be responsible for strategic decisions and dispute resolution.


Exit strategy

As the project progresses, the i&i Prague team will search for additional partners, licensees, customers or investors to ensure future development. Our strategy is to develop the project to be ready for acquisition or out-licensing, or to reach sufficient sales, within 3-5 years after signature of the agreement.


 Submit your project.

Fill in following form and we will get in touch.



i&i Prague at Arch Summit 2019


Jaromir Zahrádka, CEO of i&i Prague has been nominated among judges for Socila Impact Competition of Arch Summit 2019 in Luxemburg. This was a great opportunity to see…

A novel method for early cancer diagnostics has been developed at University of Pardubice, and partnered with i&i Prague incubator.


The new diagnostic method for Pancreatic cancer has been developed by the team of prof. Holčapek, University of Pardubice. To to make it available for patients , the university has now joined forces with the Czech biotech incubator i & i Prague. The strategic collaboration should help the project to bring the diagnostic technology to a market within a few years.

Our partners